Lauric acid diethanolamide (DEA-laurate) is a nonionic surfactant commonly used in cosmetics and personal care products. It is synthesized through the reaction of lauric acid with diethanolamine. DEA-laurate possesses excellent foaming and emulsifying properties, making it useful for creating stable and creamy formulations. The compound acts as a skin conditioning agent, contributing to the softness and moisture of the skin. Research has shown that DEA-laurate may have potential anti-inflammatory and antimicrobial properties. Its biodegradability and low toxicity make it an attractive alternative to traditional surfactants. DEA-laurate is studied extensively for its potential in various applications, including detergents, shampoos, body washes, and other personal care products. The compound's versatility, safety, and effectiveness make it a valuable ingredient in the cosmetic industry.'
lauric acid diethanolamide: component of shampoo implicated in contact dermatitis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 8430 |
| CHEMBL ID | 1996872 |
| CHEBI ID | 143726 |
| SCHEMBL ID | 284367 |
| MeSH ID | M0148332 |
| Synonym |
|---|
| einecs 277-136-4 |
| 72968-36-6 |
| 120-40-1 |
| n,n-bis(2-hydroxyethyl)dodecanamide |
| dodecanamide, n,n-bis(2-hydroxyethyl)- |
| NCGC00181001-01 |
| hsdb 5586 |
| brn 1791417 |
| n,n-di(2-hydroxyethyl)lauramide |
| lauryl diethanolamide |
| mackamide ll |
| ninol p-621 |
| aminon l 02 |
| steinamid dl 203 s |
| lauric diethanolamide |
| mackamide llm |
| lauroyldiethanolamine |
| ninol aa62 |
| n,n-diethanollauramide |
| diethanolamine lauroylamide |
| onyxol 345 |
| ninol aa-62 extra |
| lde , |
| einecs 204-393-1 |
| n,n-bis(hydroxyethyl)lauramide |
| ethylan mld |
| clindrol 101cg |
| standamid ld |
| n,n-diethylollauramide |
| richamide 6310 |
| diethanollauramide |
| alkamide le |
| n,n-bis(2-hydroxyethyl)lauramide |
| comperlan ld |
| stepan lda |
| chemstat ld 100 |
| epa pesticide chemical code 079018 |
| varamid ml 1 |
| standamidd ld |
| ninol 4821 |
| rewomid dlms |
| varamide ml 1 |
| n,n-bis(2-hydroxyethyl)lauroylamide |
| empilan lde |
| clindrol 203cg |
| nci-c55323 |
| incromide lr |
| n,n-bis(2-hydroxyethyl)laurylamide |
| hetamide ml |
| monamide 150lw |
| lauric acid diethanolamine condensate (1:1) |
| methyl laurate-diethanolamine condensate |
| lda (surfactant) |
| synotol l-60 |
| duspar la 2000 |
| caswell no. 519a |
| clindrol 210cgn |
| clindrol superamide 100l |
| lalmin d |
| super amide l-9a |
| rolamid cd |
| clindrol 200l |
| coco diethanolamide |
| n,n-bis(beta-hydroxyethyl)lauramide |
| super amide l-9c |
| monamid 150-lw |
| unamide j-56 |
| lauric acid diethanolamide |
| lankrostat jp |
| ccris 4662 |
| bis(2-hydroxyethyl)lauramide |
| rewomid dl 203/s |
| n,n-diethanollauric acid amide |
| chemistat 2500 |
| ai3-09484 |
| lauramide dea |
| lauroyl diethanolamide |
| condensate pl |
| crillon lde |
| lauramido dea |
| clindrol 100l |
| richamide std |
| emid 6511 |
| lauric acid diethanolamine condensate |
| CHEBI:143726 |
| crillon l.d.e. |
| diethanolamide of methyl laurate |
| ec 204-393-1 |
| 4-04-00-01539 (beilstein handbook reference) |
| i29i2vhg38 , |
| unii-i29i2vhg38 |
| cas-120-40-1 |
| dtxcid405491 |
| dtxsid5025491 , |
| tox21_112653 |
| FT-0600339 |
| lauric diethanolamide [ii] |
| diethanol lauramide |
| diethanol lauramide [vandf] |
| n,n-di(2-hydroxyethyl)lauramide [hsdb] |
| lauramide diethanolamide (dea) |
| lauramide dea [inci] |
| lauric acid diethanolamine |
| lauramide dea [who-dd] |
| lauramide dea [vandf] |
| AKOS014510507 |
| SCHEMBL284367 |
| MLS006010225 |
| smr001826330 |
| mfcd00045982 |
| CHEMBL1996872 |
| alkamide 327 |
| witcamide 5138 |
| n,n-diethanoldodecanamide |
| n,n-bis(.beta.-hydroxyethyl)lauramide |
| pionin d 1110 |
| ninol aa 62 |
| carsamide sal-7 |
| monamid 150-lmwc |
| emid 6541 |
| n-lauroyldiethanolamine |
| hartamide lda |
| diethanolamide lauric acid |
| stremid k |
| ninol 30-ll |
| monamid 150 lw |
| ablumide lde |
| clindrol 200 l |
| schercomid sl-extra |
| n-dodecanoyldiethanolamine |
| diethanol lauric acid amide |
| schercomid sl-ex |
| witcamide 5195 |
| lauramide, n,n-bis(hydroxyethyl)- |
| mackamide l10 |
| schercomid 1214 (salt/mix) |
| ninol aa 62 extra |
| dehydat 10 |
| W-109444 |
| lauric diethanol amide |
| LMFA08040058 |
| lauric acid diethanolamide, aldrichcpr |
| CS-W005513 |
| sr-01000944847 |
| SR-01000944847-1 |
| clindrol |
| n,n-bis(2-hydroxyethyl)dodecanamide, 9ci. n,n-bis(2-hydroxyethyl)lauramide |
| c11dea |
| c11-coconut diethanolamide |
| FT-0700556 |
| AS-10219 |
| DTXSID101022608 , |
| lauric-diethanolamide |
| Q27280284 |
| A937450 |
| Z1262465391 |
| lauric acid-diethanol amide |
| EN300-7489805 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Incubations of LDEA with liver slices from rats and humans showed that the compound is well absorbed by hepatic tissue from both species." | ( Lauramide diethanolamine absorption, metabolism, and disposition in rats and mice after oral, intravenous, and dermal administration. deCosta, K; Mathews, JM; Thomas, BF, 1996) | 0.29 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Product Category | Products |
|---|---|
| Beauty & Personal Care | 1 |
| Product | Brand | Category | Compounds Matched from Ingredients | Date Retrieved |
|---|---|---|---|---|
| TheraNeem Shampoo -- 12 fl oz | TheraNeem | Beauty & Personal Care | Chamomile, Panthenol, Lauramide DEA, Pine | 2024-11-29 10:47:42 |
| Class | Description |
|---|---|
| fatty amide | A monocarboxylic acid amide derived from a fatty acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 31.6768 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| AR protein | Homo sapiens (human) | Potency | 11.8827 | 0.0002 | 21.2231 | 8,912.5098 | AID743035; AID743063 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 23.0141 | 0.0002 | 29.3054 | 16,493.5996 | AID743078 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 29.8493 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 5.7255 | 0.0056 | 12.3677 | 36.1254 | AID624032 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 2.9849 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1424118 | Antibacterial activity against Bacillus subtilis incubated for 24 hrs by standard broth dilution assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Antibacterial Compounds from Marine Bacteria, 2010-2015. |
| AID1424120 | Antibacterial activity against Pseudomonas aeruginosa incubated for 24 hrs by standard broth dilution assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Antibacterial Compounds from Marine Bacteria, 2010-2015. |
| AID1424119 | Antibacterial activity against Escherichia coli incubated for 24 hrs by standard broth dilution assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Antibacterial Compounds from Marine Bacteria, 2010-2015. |
| AID1424121 | Antibacterial activity against Staphylococcus aureus incubated for 24 hrs by standard broth dilution assay | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 | Antibacterial Compounds from Marine Bacteria, 2010-2015. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.26) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 1 (12.50%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||